Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
August 2014—A Proteinase–3 (cANCA) native autoantigen for the in vitro diagnostics market is available from The Binding Site. Expressly designed for use as an integral component in solid-phase, ELISA-based immunoassay test procedures, the Proteinase–3 (cANCA) native autoantigen is for clinical and life-science researchers, medical laboratory professionals, and manufacturers of in vitro diagnostic immunoassay kits and tests for autoimmune conditions.
August 2014—MALDI Biotyper systems can be configured for further functionality by adding new or expanded research-use only software modules or hardware accessories.
The MBT Explorer module provides multiple bioinformatics approaches for spectra comparison, statistical data interpretation, and the generation of customer-specific reference library entries (main spectra) of strains of special interest. Such sub-libraries can be exported and re-imported in networks of collaborating labs.
August 2014—Inova Diagnostics announced the global launch of Quanta Lite Calprotectin, an FDA-cleared, quantitative ELISA that detects calprotectin levels, aids in the diagnosis of inflammatory bowel disease, and can also help differentiate, in conjunction with other laboratory and clinical findings, IBD from irritable bowel syndrome.
August 2014—Biocare Medical was issued a patent from the U.S. Patent and Trademark Office for its PIN-4 (CK5/14 + P63 + P504S) multiplex immunohistochemistry technology.
August 2014—PepFinder, from Thermo Fisher Scientific, is a software tool that streamlines relative and absolute quantitation and identification of proteins from biological samples using liquid chromatography-mass spectrometry.
August 2014—Thermo Fisher Scientific’s refrigerated small benchtop centrifuges separate samples in a compact footprint and run a wide range of applications. The refrigeration system provides a temperature range of -10°C to -40°C and can maintain temperatures when the chamber is not in use.
August 2014—HTG Molecular Diagnostics announced the availability of HTG EdgeSeq miRNA Whole Transcriptome Assay for measuring the expression of 2,275 human microRNAs described in the miRBase v20 database.
August 2014—Qiagen acquired an exclusive worldwide license to the biomarker calreticulin. Qiagen licensed the technology from CeMM Vienna, the research center for molecular medicine of the Austrian Academy of Sciences. Qiagen plans to develop a molecular diagnostic test for the CALR mutations to offer patients a clearer prognostic profile and to guide disease management.
July 2014—Xifin, the financial cloud computing company for diagnostic service providers, formed a medical advisory board that will share its extensive expertise in pathology operations and workflow, lab automation, regulatory requirements, clinician needs, and pathology informatics important to the company’s product development and strategic initiatives.
July 2014—Meridian Life Science now has a sampling kit with HIV-1 p24 reagents for developing sensitive and specific HIV-1 p24 sandwich immunoassays. The kit includes a 0.25-mg vial of capture antibody, MAb to HIV-1 p24; a 0.25-mg vial of detection antibody, MAb to HIV-1 p24; and a 0.25-mg vial of recombinant HIV-1 p24 antigen (strain HxB2) expressed in Pichia pastoris. Meridian Life Science, 901-382-8716
